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Abstract 
After being used for decades in clinical screening, dried blood spots (DBS) have recently received 
considerable attention for their application in pharmacokinetic and toxicokinetic studies in rodents. 
The goal of this study was to develop and apply a DBS-based assay for a pharmacokinetic study of 
paclitaxel (PTX) and its metabolites in SCID/Beige mice. A fast and sensitive UHPLC-MS/MS method 
has been developed for the simultaneous determination of PTX, its three metabolites (6α-hydroxy-
paclitaxel, 3'-p-hydroxy-paclitaxel, and 6α,3'-p-dihydroxy-paclitaxel) and its stereoisomer 7-epi-
paclitaxel. The 10 µL DBS sample was extracted with methanol for 20 min at 37°C. After dilution of 
the extracts with water in a ratio of 1:1, the analytes were separated on a reversed-phase 2.1 mm 
I.D. column using gradient elution. The total run time was 2.5 min. The analytes were detected by 
use of multiple reaction monitoring mass spectrometry. The extraction recoveries of the compounds 
were all greater than 60%, resulting in a quantification limit of 1 ng/ml. The calibration curves ranged 
from 1 to 1000 ng/ml. The intra-day and inter-day imprecision (%CV) across three validation runs 
over four quality control levels were less than or equal to 14.6%. The accuracy was within ±11.9% in 
terms of relative error. The described method is advantageous in terms of its ease-of-use and speed 
compared to other published PTX assays. The method’s usefulness was demonstrated by applying it 
to a preclinical pharmacokinetic investigation of PTX and its metabolites in SCID/Beige mice with an 
intraperitoneal administration of 50 mg/kg Abraxane®.  
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1.Introduction 
Paclitaxel (PTX, Fig.1) is a natural product discovered in 1968 by isolation from the bark of the pacific 
yew tree Taxus brevifola[1]. It is a widely used antineoplastic drug for the treatment of multiple types 
of tumors including ovarian, stomach, endometrial, colon, breast cancer and so on[2-4]. Despite its 
clinical efficacy, current PTX-based therapies are characterized by non-linear pharmacokinetics, a 
narrow therapeutic window, and severe dose-limiting toxicities (DLTs)[5, 6].  
 
PTX is predominantly metabolized in the liver by cytochrome P450 (CYP) enzymes. The primary 
metabolite 6α-hydroxy-paclitaxel (6α-OH-PTX, Fig.1) is formed by CYP2C8, whereas the secondary 
metabolite 3'-p-hydroxy-paclitaxel (3'-p-OH-PTX, Fig.1) is generated by CYP3A4[7, 8]. These two 
metabolites can be further metabolized to a minor metabolite 6α,3'-p-dihydroxy-paclitaxel (6α,3'-p-
di-OH-PTX, Fig.1). In addition, the C-7 chiral center in the taxane ring of PTX is notably labile and can 
readily undergo epimerization in an aqueous environment, resulting in 7-epi-paclitaxel (7-epi-PTX, 
Fig.1), a biologically active[9] and thermodynamically more stable stereoisomer under physiological 
conditions[6, 10].  
 
Intraperitoneal chemotherapy (IPC) with PTX has a strong pharmacokinetic rationale in the treatment 
of peritoneal carcinomatosis. Hereto, PTX is directly administered into the abdominal cavity[11]. In 
this way, by lowering the systemic exposure, DLTs should be reduced [12]. However, controversy 
remains regarding the optimal treatment strategies that will optimize efficacy whilst minimizing 
systemic exposure. Quantification of PTX together with its metabolites is of major importance to gain 
insights into the absorption process and the extent of first-pass metabolism during IPC treatment.  
Current attempts to gain fundamental insights in the disposition of PTX following IPC treatment have 
focused on rodent models[13, 14]. In order to exploit the full potential of these animal models, an 
efficient sampling procedure coupled to a rapid and sensitive analytical method is highly desirable.  
 
Dried blood spot (DBS) sampling is a form of microsampling where small volumes of blood samples 
are applied on absorbent paper[15]. The most notable benefits of DBS sampling are the low required 
volume thus resulting decrease in the number of animals to be included in pharmacokinetic 
(PK)/toxicokinetic (TK) studies[16-18], and the improved stability in the dried blood spot matrix as 
compared to whole blood/plasma samples[19]. However, some challenges need to be overcome for 
the implementation of DBS analysis. The most common disadvantages are hematocrit, complex 
matrix (whole blood plus paper), required high sensitivity, and the comparability of DBS and plasma 
derived concentrations[20].  
  
Different bioanalytical techniques have been described for the determination of PTX, including 
immunoassays[21], capillary electrophoresis[22], HPLC with UV detection[23] and liquid 
chromatography-tandem mass spectrometry (LC-MS/MS)[24-26]. Of these, the LC-MS/MS technique 
has been the most frequently applied method due to its sensitivity and selectivity[27]. There have 
been several LC-MS/MS assays published for the quantification of PTX and its metabolites[3, 28-30] 
in various biological matrices such as plasma, serum, urine and tissue. As far as we know, there is 
only one publication reported for the determination of PTX in human DBS[31]. This method has a 
relatively narrow calibration range (0.2-20 ng/ml) and its clinical utility has not been demonstrated. 
Our report here is describing the quantification of PTX including its metabolites in dried blood spots 
obtained from animal experiments.  
 
The goal of the present study was to develop a rapid and sensitive LC-MS/MS method for the 
simultaneous quantification of PTX and its metabolites (3'-p-OH-PTX, 6α-OH-PTX, and 6α,3'-p-di-OH-
PTX) as well as the stereoisomer 7-epi-PTX, in mice DBS samples based on a simple extraction 
procedure. The use of DBS, a short gradient elution, and satisfactory sensitivity demonstrate that this 
LC-MS/MS method is superior to previous methods. This method to quantify PTX and its metabolites 
was successfully applied to a pharmacokinetic study where 10 SCID/Beige mice received an 
intraperitoneal dose of 50 mg/kg Abraxane®.  
2.Material and Methods 
2.1 Reagents and chemicals 
Paclitaxel, 13C6-Paclitaxel (internal standard (IS)), 3'-p-hydroxy-paclitaxel, 6α-hydroxy-paclitaxel, 6α-
hydroxy-paclitaxel-d5 (IS), 6α,3'-p-dihydroxy-paclitaxel, and 7-epi-paclitaxel were all purchased from 
Toronto Research Chemicals (Toronto, Canada). ULC-MS grade water and methanol were obtained 
from Biosolve (Valkenswaard, The Netherlands). The PKI Bioanalysis Card (GR2261004) was supplied 
from PerkinElmer Health Sciences (Greenville, South Carolina, USA). All other solvents or chemicals 
were analytical grade or better.  
 
2.2 Instrumentation and set-up 
2.2.1 UHPLC-MS/MS 
An Acquity BEH C18 column (50 × 2.1 mm, 1.7 μm) with an Acquity BEH C18 VanGuard pre-column (5 
× 2.1 mm, 1.7 μm) installed in an Acquity UPLC H-class system (Waters, Milford, MA, USA) was used 
for chromatographic separation. Mobile phases, delivered at 0.45 ml/min, consisted of 0.2% formic 
acid either in 90/10 (v/v) water/methanol (eluent A) or in methanol (eluent B).  The total run time for 
each separation was 2.5 min, and the linear gradient elution program was as follows: 0-1.25 min, 
50% B to 80% B; 1.25-1.5 min, 80% B to 100% B; 1.5-2.0 min, 100% B to 50% B; 2.0-2.5 min, 50% B. A 
divert valve program switching alternatively between detector and waste was incorporated as 
follows: 0-0.75 min: to waste; 0.75-2.0 min: to detector; 2.0-2.5 min: to waste. The column 
temperature was kept at 50 °C, and the injection volume was 10 μL.  
 
The LC eluate was led directly into a Waters Xevo TQS tandem mass spectrometer (Waters, Milford, 
MA, USA) with electrospray ionization (ESI) in the positive-ion, multiple reaction monitoring (MRM) 
mode. The MS/MS instrument was operated with a capillary voltage of 3.0 kV and source 
temperature of 150 °C. The desolvation gas (nitrogen) flow rate was set to 1000 L/h at a temperature 
of 600 °C, and collision gas (argon) flow was maintained at 0.15 ml/min. Details of the MRM-
transitions, dwell time, cone voltage, and collision energy for each compound are described in Table 
1.  
 
2.2.2 Microflow UHPLC-MS/MS 
A microflow UHPLC (μUHPLC)-MS/MS, i.e. the Waters ionKey/MS system, was evaluated for 
increasing sensitivity during method development. The system was comprised of the ACQUITY UPLC 
M-Class, the Xevo TQ-S, and the ionKey/MS™ separation device (Waters, MA, USA). Mobile phase A 
was 10% methanol in water containing 0.2% formic acid and mobile phase B was 0.2% formic acid in 
methanol. In a full loop injection mode, 5 µL was injected on to a trap column (M-Class Trap 
Symmetry C18, 100 Å, 5 μm, 300 μm × 25 mm) using a trapping flow of 30 μl/min with 20% methanol 
for 3.0 min. After trapping, the flow was reversed and directed to a Waters BEH C18 iKey™ analytical 
column (150 μm × 100 mm, 130 Å, 1.7 μm).  
 
The flow over the analytical column was 2 μl/min and the column was operated at 50°C. PTX and its 
metabolites were eluted from the analytical column using the following gradient: 0-5 min: 90-0.5% A 
and 10-99.5% B, 5-6 min: 0.5-90% A and 99.5-10% B, 6-6.5 min 90% A and 10% B, 6.5-7 min 90-0.5% 
A and 10-99.5% B, 7-12 min 0.5% A and 99.5% B, 12-12.5 min: 0.5-90% A and 99.5-10% B. In the 
μUHPLC eluate, the analytes were detected using the same MS/MS parameters as described above 
(Table 1).   
 
2.3 Preparation of standards and quality controls 
Primary stock standards were prepared in ethanol at concentrations of 0.96, 0.943, 0.0345, 1.104, 
and 0.257 mg/ml for PTX, 7-epi-PTX, 3'-p-OH-PTX, 6α-OH-PTX, and 6α,3'-p-di-OH-PTX, respectively. 
Stock standards were mixed in the appropriate proportions and were further diluted with acetonitrile 
to obtain working solutions. Blank human whole blood from healthy volunteers (Ghent University 
Hospital, Belgium) was spiked with the different working solutions to obtain calibrator samples at 7 
concentration levels. In order to preserve the integrity of the blood matrix, the blood standards 
contained at most 5% (v/v) of working solution. The final concentrations for the calibrators ranged 
from 1 to 1000 ng/ml for all analytes. The blood quality control (QC) samples were also prepared as a 
mixture from the different working solutions at concentrations of 1 (lower limit of quantitation QC, 
LLQC), 2.5 (low QC, LQC), 25 (medium QC, MQC) and 1000 (high QC, HQC) ng/ml. Internal standard 
stock solutions of 13C6-PTX and 6α-OH-PTX-d5 were prepared in ethanol at concentrations of 0.1 and 
0.5 mg/ml, respectively. After mixing and further dilution of these stock solutions with methanol, an 
internal standard working solution at a concentration of 2 ng/ml was obtained. All stock and working 
solutions were stored at -20°C. 
 
2.4 DBS sample preparation and extraction 
Aliquots (10 μL each) of whole blood samples were spotted onto PKI Bioanalysis Cards (PerkinElmer 
Health Sciences, USA) with a calibrated pipette and left to dry for at least 3 h at room temperature 
prior to analysis. The entire DBS was punched out and collected into a 1.5-ml Eppendorf tube. 
Extraction was performed by adding 200 μL of IS working solution. The sample tubes were closed and 
thermostatted at 37 °C for 20 min whilst continuously being shaken by a Biosan TS-100 Thermo 
shaker (Biosan, Riga, Latvia) at 500 rpm. Then, 100 μL of the extract was added to 100 μL water and 
vortex-mixed for 30s. After transferring the resulting solution to an autosampler vial, a volume of 10 
μL was injected into the UHPLC-MS/MS system.  
 
2.5 Method validation 
The method was validated for human DBS and cross-validated for mice DBS following the “Guideline 
on bioanalytical method validation” released by European Medicines Agency (EMA), 2011 and EBF 
recommendation on the validation of bioanalytical methods for dried blood spots[32, 33]. 
Selectivity was evaluated by the analysis of blank DBS from two different human whole blood sources 
and three mice whole blood sources. The LLOQ was defined as the lowest point of the calibration 
curve for which the bias (%) was within ± 20% and imprecision (coefficient of variation, CV%) < 20%. 
Calibration models were evaluated by comparing recovery values and residual distributions. Bias and 
imprecision were determined from six replicates at four QC concentration levels over three days. Bias 
was determined as % relative error of nominal concentration and imprecision was expressed as % CV. 
Carry-over was assessed by injecting blank samples directly after an injection of the highest 
concentration level of the calibrators.  
 
Matrix effect was evaluated following Viswanathan et al., through the calculation of the internal 
standard-normalized (IS-normalized) matrix factor (MF)[34]. Extraction recoveries were determined 
at low and high concentrations in six replicates by comparing the peak area for extracted QC samples 
with the directly injected solution containing the same nominal concentrations. 
 
Dilution integrity (10-fold) was assessed for PTX, 7-epi-PTX, and 6α-OH-PTX by processing six human 
DBS samples at 10-fold above the HQC sample. The dilution integrity of these three compounds were 
chosen due to their higher expected concentrations in vivo on a standard treatment regimen. In this 
procedure, the methanol-based extract of a DBS sample was first diluted with water in a ratio of 1:1 
and further diluted with a blank matrix, followed by an addition of IS. In our study, three blank 
matrices were evaluated: i) a 50/50 (v/v) water/extract of blank DBS samples, ii) a 50/50 (v/v) 
water/extract of PKI bioanalysis cards, and iii) a 50/50 (v/v) water/methanol mixture. Dilution 
integrity was acceptable if the mean concentrations of analytes were within ± 15% of target.  
 
Analyte stability was evaluated with human DBS QC samples at low and high concentrations in six 
replicates. The stability of the processed QC samples in an autosampler (10 °C) was determined for 
24 h. Storage stability was tested using QC samples stored at room temperature (± 22°C) for 20 days. 
Samples were dried overnight and stored in a sealed plastic bag. QC samples were analyzed after 10 
and 20 days of storage against a freshly prepared calibration curve, the spots of which were dried at 
least 3 h before the analysis.  
 
A cross-validation was performed to ensure that the method is applicable to mice DBS samples. The 
DBS calibrators were made in human whole blood, and DBS QC samples at four concentration levels 
in six replicates were prepared in mice whole blood. Analytes’ concentrations in mice DBS samples 
were quantified according to the human DBS calibration curve. For QC samples, the obtained mean 
accuracy and precision should be within 15% except the LLQC samples that should be within 20%.  
 
3. Results and discussion 
 
3.1 Method development  
3.1.1 Mass spectrometric detection and chromatography 
The individual parameters for the mass spectrometric detection were optimized by infusion of the 
analytes and internal standards in 50/50 (v/v) methanol/water containing 0.1% formic acid. 
Detection was evaluated in the positive electrospray ionization (ESI+) mode alone due to the different 
basic functional groups present in all compounds. The MS parameters such as cone voltage and 
collision energy were optimized in order to achieve the highest MS response for each analyte. The 
most abundant adduct ion for all of them was [M+Na]+, and their major product ions come from the 
rupture of an ester bond (depicted in Fig. 1). The optimization parameters and selected MRM 
transitions are listed in Table 1.  
 
Considering the structural diversity of the compounds, gradient elution was applied, using methanol 
containing 0.2% formic acid as the organic eluent. Different gradient conditions were evaluated to 
achieve a baseline separation of PTX and its stereoisomer 7-epi-PTX as well as to maximize 
chromatographic resolution of other compounds whilst minimizing overall run time. After 
optimization of gradient elution parameters, we achieved full chromatographic separation for all 
target analytes in only 2.5 min. This 2.5 min includes the equilibration time required for the next run. 
A chromatogram of a calibrator sample is presented in Fig. 2. As shown in the chromatogram, PTX is 
eluted earlier than 7-epi-PTX, demonstrating 7-epi-PTX is less polar than PTX. This is possibly due to 
intramolecular hydrogen bonding between the 7α-hydroxyl group and the carbonyl oxygen of the 4α-
acetoxy group[35].  
 
3.1.2 Extraction procedure 
Different challenges should be overcome when developing a sample extraction protocol for DBS 
samples.  
 
Firstly, as stated in the European Bioanalysis Forum (EBF) recommendation on DBS, “hematocrit is 
currently identified as the single most important parameter influencing the spread of blood on DBS 
cards, which could impact the validity of the results generated by DBS methods, affecting the spot 
formation, spot size, drying time, homogeneity and, ultimately, the robustness and reproducibility of 
the assays”[32]. In order to remove the variability resulting from the spread of and non-homogeneity 
in the blood, we have chosen to analyze the entire blood spot in our study. This approach would 
produce more consistent DBS concentrations regardless of HCT levels. Additionally, the correlation 
between DBS and plasma concentrations is to be established, and is even mandatory for the DBS 
assay to be implemented clinically[20]. Usually bridging studies, where both plasma and blood (DBS) 
are collected from each time point, need to be conducted to evaluate the relationship or agreement 
of the DBS and plasma concentrations[36]. In our situation working with mice, collecting both the 
plasma and DBS samples at each time point is extremely challenging due to the very limited amount 
of blood that can be taken. In this case, it is more advantageous to predict the plasma concentrations 
from DBS data using ex vivo blood to plasma ratio data from an experimental aspect[36]. Therefore, 
the correlation between the DBS and plasma concentrations was not investigated in our study. 
 
Secondly, the ideal option for introducing an IS in DBS method development is to add IS into the 
blood before spotting it onto the sample card. The benefit of this option is that the IS can interact 
with the liquid blood matrix and the analytes[37]. However, it is very cumbersome  to implement this 
in our rodent PK/TK study due to the limited amount of blood that can be sampled during 
venipuncture. Therefore, like in most DBS assays, in our assay the IS were introduced via an 
extraction solvent. A potential drawback of this choice is that the IS may not be fully incorporated 
into the matrix components and sample card, thus unable to compensate for fluctuations in 
extraction from the DBS samples[33]. It is, therefore, important to evaluate the efficiency of the 
extraction process during method development. Under 37°C with a rotate speed of 500 rpm for 
20min, the extraction efficiencies of methanol and acetonitrile were evaluated for the DBS samples. 
As shown in Table 3, extremely low recoveries (3.0-5.2%) were found when using acetonitrile (low 
concentration even resulted in no detectable signal). The recoveries were approximately 13-23 fold 
lower in comparison to methanol. This is most likely due to the insolubility of the dried blood matrix 
in pure acetonitrile[37], resulting in poor extraction of the compounds and low elution efficiency. 
Based on these results, methanol was selected as the extraction solvent for the further validation.  
 
Thirdly, compared with analysis of liquid samples, the sensitivity of the DBS method is expected to be 
lower because of the small spotting volume (i.e. 10-20 µL). An evaporation and reconstitution 
procedure is commonly implemented to counteract the loss of sensitivity. In contrast, a simple 
extraction procedure with a further dilution with water to match the initial phase of the gradient 
elution was applied in our study. This procedure resulted in a simple and time-saving sample 
extraction process. The loss of sensitivity is partly compensated through the use of an advanced mass 
spectrometer (i.e. Waters TQS system).   
 
3.1.3 Microflow-UHPLC as a means to increase sensitivity  
In an attempt to increase the sensitivity of the assay, we evaluated a novel micro-fluidics platform, 
i.e. the Waters ionKey/MS system. Theoretically, compared to analytical scale LC (e.g. 2.1 mm I.D. 
chromatography), micro LC benefits from signal enhancements for small molecule analysis through 
enhanced ionization efficiency and reduced matrix interference[38]. To test this hypothesis, we 
evaluated the sensitivity between the UHPLC-MS/MS and ionKey/MS system by injecting 1 ng/ml of 
PTX on both systems. As shown in supplementary Fig. A.1, for the same injection volume, a similar 
S/N ratio was obtained on both systems. Therefore, a trap-and-elute strategy was explored. This set-
up can handle relatively large injection volumes (e.g. 20 μL) and facilitate the loading of the samples 
containing a relatively high proportion of organic solvent compared to direct injection[39].  
 
The configuration of the optimized dual pump trapping and subsequent sample elution is presented 
in Fig.A.2. The schedule of events in the optimized dual-pump trapping workflow is shown in 
supplementary Table A.1. The representative chromatograms of PTX and its metabolites, eluted 
under above conditions are shown in Fig. A.3. In order to compare the sensitivity difference between 
the dual pump trapping strategy and the analytical scale LC (i.e. 2.1 mm I.D. chromatography), the 
signal to noise of PTX obtained from these two approaches was normalized with the amount of PTX 
on column, giving a ratio of about 0.8 (dual pump trapping/analytical scale LC). This is in line the 
finding with the direct injection mode.  
 
The main hurdle we encountered when trying to improve the sensitivity for PTX and its metabolites 
using the dual pump trap-and-elute strategy was the carry-over. Initially, a very high carry-over (~ 5.0 
%) was found for a 20 µL full loop injection of PTX with only an iKey flushing procedure. By adding the 
trap column washing procedure, the carry over reduced to ~0.6 %, indicating contamination in the 
trap column or sample loop. In order to identify the sources of carry over, the trap column was 
disconnected and a tubing (I.D. 40 µm × length 6") was connected instead. The no injection (i.e. run 
gradient without injection) and blank injection were performed after an injection of PTX with only an 
iKey flushing procedure. Blank signals were found for both no injection and blank injection, 
demonstrating that the carry over originates from the trap column. Various attempts for cleaning the 
trap column and also the injection path were further investigated, including using acetonitrile 
(stronger organic) and ethanol (higher solubility of PTX) as the wash solvents for the trap column, 
increasing the flushing flow rate (e.g. 50 µL/min) and/or flushing time (e.g. 7 min) of the wash 
solvents, adding 0.1% plasma in the sample, running multiple rinses through the trap column by 
cycling between auxiliary pump A (Aux A, 20% methanol) and B (Aux B, 100% methanol) multiple 
times. However, none of these solutions helped to reduce the carry over. A scale down to 5 µL full 
loop injection further reduced the carry over to ~0.12%, albeit at the expense of sensitivity. Reducing 
the operational a range of PTX in DBS samples to 1 - 100 ng/ml, the carry-over of the 100 ng/ml PTX 
DBS sample injections became less than 20% of the LLOQ, using the optimized trapping workflow 
shown in Table A.1.  
 
The sensitivity we were able to achieve with the ionKey/MS system configured as such was 1 ng/ml 
in the DBS sample. This  is comparable with that of the UHPLC-MS/MS method using a 10 µL 
injection. Considering the rapid analytical run time, wide calibration range, and lack of carry over that 
UHPLC-MS/MS provides for PTX, we choose to abandon μUHPLC-MS/MS in favor to UHPLC-MS/MS 
for the further method optimization.  
 
3.2 Validation 
3.2.1 Selectivity, carry over, calibration model, and LLOQ  
None of the blank samples gave any interference at the retention times of PTX and its metabolites. 
No detectable carry-over for the analytes was found after injection of the highest calibrator sample. 
The optimal calibration curves were fitted using a quadratic function for describing the relationship 
between responses and concentrations for all compounds. Due to the wide calibration concentration 
range (i.e. 1 to 1000 ng/ml), a log-transformation was required to correct for heteroscedasticity. The 
limit of quantification for the DBS sample was 1 ng/ml for all compounds. A typical chromatogram of 
a LLOQ calibrator sample is presented in Fig. 2.  
 
3.2.2 Bias, imprecision, and cross-validation 
Bias and imprecision results from human and mice DBS QC samples are presented in Table 2. In 
human DBS samples, within- and between-run bias were 99.0-111.9 % and 98.4-111.0 % of nominal 
concentrations, and within- and between-run imprecision were 5.6-14.6 % CV and 8.8-13.6 % CV.  
 
For the cross validation of mice DBS sample, the within-run bias and imprecision were 94.3-118.3 % 
of target concentration and 1.8-16.0% CV. For 6α-OH-PTX and 6α,3'-p-di-OH-PTX, the measured bias 
at the LLOQ level are respectively 118.3% and 117.7%, which fell within the regulated bioanalytical 
guidelines. For 3'-p-OH-PTX at the high QC level, the imprecision was considered acceptable albeit it 
slightly deviated (16.0% CV) from the pre-set limit of 15%. The outcome of the cross validation 
demonstrated the feasibility of using human DBS calibrators to quantify mice DBS samples. This 
removes the need for fresh mouse blood for the production of the calibrator samples.   
 
3.2.3 Extraction recoveries and matrix effects 
Extraction recoveries and IS-normalized matrix effects in DBS samples are summarized in Table 3. The 
extraction recoveries for all compounds processed using methanol were 60.5-87.6%, demonstrating 
a satisfactory extraction efficiency. The IS-normalized matrix factors for the compounds except 6α,3'-
p-dihydroxy-paclitaxel were within 85%-115% with a low variation indicating that the IS compensate 
well for the matrix effects. Moderate signal suppression (67.5-79.1%) was observed for the 
metabolite 6α,3'-p-dihydroxy-paclitaxel. This could be related to its chemical structure. 6α,3'-p-
dihydroxy-paclitaxel has an extra hydroxyl group with respect to the IS 6α-hydroxy-paclitaxel-d5. This 
makes 6α,3'-p-dihydroxy-paclitaxel more polar, thus early eluting, and therefore probably more 
prone to ion suppression in contrast to the IS. Although this limited matrix effect was observed 
during validation, we considered this acceptable given the good reproducibility of the observed 
absolute matrix effect and in view of the scope of the assay.  
 
3.2.4 Stability 
The mean of the calculated concentrations of all compounds were within -12.1% to 7.8% of target 
when fortified at low and high QC concentrations and kept for 20 days at room temperature, or 24 h 
post-extraction in the autosampler at 10 °C.  
 
3.2.5 Dilution integrity 
Evaluation of dilution integrity during method validation can ascertain the method is applicable to 
the samples with analyte concentrations higher than the upper limit of quantification. The principles 
of dilution used for traditional liquid samples also apply for DBS. However, a DBS sample cannot be 
simply diluted as is typically done for bio-fluids, due to the dried matrix. The common approach is to 
dilute the processed high concentration samples with the extracts of blank DBS samples. It works 
well for a few samples with a relatively small dilution factor, but can be costly or impractical when 
the samples require large dilution factors[37]. This implies a lot of blank whole blood for each run, 
while the blank matrix (especially the blood) from mice is not freely available and very expensive to 
obtain.  
 
In our study, two alternative blank matrices, a 50/50 (v/v) water/extract of PKI bioanalysis cards and 
a 50/50 (v/v) water/methanol mixture, were compared to the above dilution procedure using a 
50/50 (v/v) water/extract of blank DBS samples, and subsequently validated. As graphically shown in 
Fig. 3, the dilution integrity with these three matrices was acceptable with the mean bias within 
±15% of expected diluted concentrations. There was no significant difference in accuracy and 
precision obtained from the two alternative procedures compared with the standard procedure. The 
procedure with a 50/50 (v/v) water/methanol mixture can easily be configured to DBS sample 
analysis without processing additional (blank DBS) cards in each analytical run. It was thus selected as 
the blank solvent for the dilution.  
 
3.3 Application of the method 
As a proof-of-concept, the method was applied to DBS samples from a mice PK study. In this study, a 
50 mg/kg Abraxane® dose was administered intraperitoneally. To obtain the DBS samples, after 
venipuncture (taking approximately 12 - 15 µL of blood), 10 µL of blood was accurately transferred to 
a DBS card. The concentration time curves for PTX and its metabolites from ten SCID/Beige mice are 
shown in Fig. 4. 6α-OH-PTX is shown to be the major metabolite of PTX in mice. 3'-p-OH-PTX is a 
secondarily abundant metabolite, which is measurable from 1 to 4 hours post dosing. 6α,3'-p-di-OH-
PTX was detected in some samples but was below the LLOQ and is therefore not shown. 7-epi-PTX is 
abundant in vivo and it is detectable up to 8 hours after dosing. To our knowledge, it is the first time 
that the PK profiles of the metabolites and 7-epi-PTX in mice are presented. Further interpretation of 
the pharmacokinetic results, however, is beyond the scope of this publication. 
 
It is worth noting that two partially overlapping peaks were eluted at 1.54 and 1.57 min, respectively 
(shown as an insert in Fig.1) in the mice sample. These chromatographic peaks were observed in the 
MRM-transition optimized for 6α-OH-PTX. The peak at 1.57 min is thought to represent 6α-OH-PTX 
due to the same retention time with that of the calibrators, whereas the peak at 1.54 min is assumed 
to be the stereoisomer of 6α-OH-PTX at the C-6 chiral center in the taxane ring. This phenomenon is 
possible because there are two potential directions for a hydroxyl group to be added onto the C-6 
center during metabolism. This previously unreported stereoisomer of 6α-OH-PTX was observed in 
our study most likely due to the improved resolution of the UHPLC system. Calculated 6α-OH-PTX  
concentrations were therefore taken as the sum of these two species, thereby assuming an identical 
MS/MS response factor.  
 
4. Conclusion 
 
The proposed method of analysis provides a rapid and sensitive LC-MS/MS assay for the 
simultaneous quantification of PTX, its three metabolites and the stereoisomer 7-epi-PTX in DBS 
samples over the concentration range of 1-1000 ng/ml. The validated method with a low sample 
volume needed was demonstrated to be selective, accurate and precise. The simple extraction 
procedure and short LC-MS/MS run time imply that a large amount of samples can be analyzed in a 
short time frame. The feasibility of using human DBS calibrators to quantify mice DBS samples was 
shown. This facilitates the analysis of mice samples as the source of blank mice blood are limited in 
comparison to human blood. The utility of this assay was demonstrated through its successful 
application for the analysis of DBS samples from the pharmacokinetic studies in mice.  
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 Table 1 Detection parameters for the compounds under study. 
Compound Cone voltage (V) Collision energy (CE) MRM-transitions Dwell (secs) 
PTX 36 28 876.3 > 308.1 0.017 
13C6-PTX 74 28 882.3 > 314.2 0.017 
7-epi-PTX 10 30 876.6 > 308.2 0.017 
3'-p-OH-PTX 60 30 892.5 > 324.1 0.030 
6α-OH-PTX 36 30 892.5 > 308.1 0.017 
6α-OH-PTX-d5 28 32 897.5 > 313.2 0.017 
6α,3'-p-di-OH-PTX 18 30 908.5 > 324.1 0.047 
 
  
 
Table 2 Bias and imprecision data for human and mice DBS QC samples of the method. 
 
Compound Nominal 
concentration 
(ng/ml) 
Human DBS sample   Mice DBS sample (cross-validation) 
Within-run (n=6)   Between-run (n=18) 
 
Within-run (n=6) 
Bias (%) Imprecision (RSD%)   Bias (%) Imprecision (RSD%)   Bias (%) 
Imprecision 
(RSD%) 
PTX 1-2.5-25-1000 109.2-103.1-107.8-101.0 5.9-12.4-12.8-13.6 
 
108.4-101.1-107.0-99.6 11.3-10.9-13.0-12.4 
 
101.5-95.6-103.0-100.7 12.5-6.7-1.8-13.9 
7-epi-PTX 1-2.5-25-1000 103.7-99.7-101.2-101.5 11.2-11.8-11.2-14.6 
 
105.1-99.3-104.9-99.0 12.9-9.8-12.2-13.6 
 
109.3-94.3-96.1-99.5 8.1-3.6-3.5-15.0 
3'-p-OH-PTX 1-2.5-25-1000 103.6-101.9-109.4-99.3 5.6-11.4-13.2-13.6 
 
105.8-99.3-108.5-99.3 8.8-8.9-10.6-11.2 
 
112.9-103.8-102.8-106.1 8.2-6.3-11.7-16.0 
6α-OH-PTX 1-2.5-25-1000 103.4-101.1-105.9-99.7 9.3-11.1-11.7-14.6 
 
105.5-99.6-106.6-98.8 11.7-9.9-11.1-12.5 
 
118.3-105.3-102.7-109.0 4.6-4.7-3.9-15.0 
6α,3'-p-di-OH-PTX 1-2.5-25-1000 104.8-110.1-111.9-99.0 6.8-14.6-12.6-12.5   104.2-101.1-111.0-98.4 10.0-12.1-12.1-11.6   117.7-112.7-100.3-101.8 11.6-8.0-5.8-13.3 
 
  
Table 3 Extraction recoveries and IS-normalized matrix effects of the method.  
 
Compound Matrix effect (%, n=6) Extraction (via methanol) recovery (n=6)  Extraction (via acetonitrile) recovery (n=6)  
Low (RSD%) High (RSD%) Low (RSD%) High (RSD%) High (RSD%) 
PTX 99.3 (1.3) 100.5 (0.9) 87.6 (8.4) 70.5 (10.1) 4.6 (3.0) 
7-epi-PTX 104.4 (3.4) 97.1 (5.5) 85.4 (8.2) 70.5 (13.8) 5.2 (2.3) 
3'-p-OH-PTX 85.7 (2.5) 91.7 (4.6) 70.6 (6.6) 69.0 (6.3) 3.0 (3.2) 
6α-OH-PTX 101.5 (1.5) 101.0 (2.4) 71.0 (5.4) 64.5 (9.1) 3.7 (3.7) 
6α,3'-p-di-OH-PTX 67.5 (6.1) 79.1 (2.5) 64.7 (4.2) 60.5 (7.7) 3.0 (3.5) 
 
 
 
Figure captions 
 
 
 
 
Fig. 1 Chemical structures of paclitaxel, 7-epi-paclitaxel, 3'-p-hydroxypaclitaxel, 6α-hydroxy paclitaxel, 
and 6α,3'-p-dihydroxypaclitaxel, and their fragmentation pattern.  
 
 
 
 Fig. 2 Chromatogram of a LLOQ calibrator sample. An asterisk denotes compounds for which a stable 
isotope labelled internal standard was included. A chromatogram of 6α-OH-PTX in a real mouse DBS 
sample post intraperitoneal administration of 50 mg/kg PTX was also inserted. 
 
 
 
 
 
 
 Fig. 3 Dilution integrity (10-fold) of PTX, 7-epi-PTX, and 6α-OH-PTX by processing six human DBS 
samples at 10-fold above the HQC sample. Three blank matrices were evaluated for the dilution: 
Solvent A (): 50/50 (v/v) water/methanol; Solvent B (): the 50/50 (v/v) water/extract of PKI 
bioanalysis cards; Solvent C (): the 50/50 (v/v) water/extract of blank DBS samples. The black signs 
stand for the mean bias from six replicates of the DBS samples diluted with different blank matrices. 
The individual points (grey signs) beyond ±15% were labeled with the found bias. 
 
 
 Fig. 4 The concentration-time curves of PTX and its metabolites in mice post intraperitoneal 
administration of a 50 mg/kg dose of PTX. A Loess smoothing line was added to the plot for each 
analyte.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
